RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Endophthalmitis: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Infectious Keratitis and Endophthalmitis Following Boston Type I Keratoprosthesis: Incidence, Risk Factors, and Long-Term Outcomes.
Cortina Maria Soledad et al., The ocular surface (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42887719/
- 2.
Endogenous Klebsiella pneumoniae Endophthalmitis with a Large Subretinal Abscess.
Gong Ruowen et al., Ophthalmology. Retina (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42873177/
- 3.
Culture-Proven Endophthalmitis Associated With Penetrating Keratoplasty: Clinical Features, Microbiologic Aspects, and Outcomes.
Zhang Charles et al., Cornea (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42866871/
- 4.
Extracting the Unexpected: A 35-mm Curved Nail as an Intraocular Foreign Body.
Afandi Rahaf A et al., The American journal of case reports (12 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42860706/
- 5.
Risk of Endophthalmitis After Cataract Surgery in Immunosuppressed Patients.
Yuan Melissa et al., Ophthalmic surgery, lasers & imaging retina (12 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42862931/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Endophthalmitis
Endophthalmitis is a severe inflammation of the inner tissues and fluids of the eye, most often caused by infection after eye surgery, an injection into the eye, an injury, or spread of infection through the bloodstream. Symptoms include sudden eye pain, redness and loss of vision. It is an emergency treated with antibiotic or antifungal medicine injected into the eye, and sometimes surgery to remove the vitreous gel.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
PURPOSE: To evaluate the incidence, clinical characteristics, and risk factors for infectious keratitis and endophthalmitis following Boston Type I keratoprosthesis (KPro) implantation. METHODS: We retrospectively reviewed 153 eyes (141 patients) that underwent KPro implantation at the University of Illinois Chicago between 2005 and 2023. Demographic, clinical, microbiologic, and surgical data were analyzed. Incidence rates were calculated per eye-year at risk, and Cox proportional hazards models were used to assess risk factors. RESULTS: Among 153 eyes from 141 patients, 30 developed at least one infection: 12 developed endophthalmitis alone, 5 developed infectious keratitis alone, and 13 developed both. The incidence rates of endophthalmitis and infectious keratitis were 2.77 and 1.97 cases per 100 eye-years at risk, respectively. In univariable Cox analysis, immune-mediated ocular disease (HR, 3.05; 95% CI, 1.04-8.95; P = .043) was associated with endophthalmitis, and preexisting eyelid/adnexal abnormality was associated with infectious keratitis (HR, 5.67; 95% CI, 2.02-15.95; P = .001). In the model adjusted for age, immune-mediated ocular disease, and prior herpes simplex virus (HSV) keratitis, immune-mediated ocular disease was associated with endophthalmitis (adjusted HR, 3.62; 95% CI, 1.19-11.04; P = .024), whereas prior HSV keratitis showed a borderline association (adjusted HR, 3.05; 95% CI, 1.00-9.26; P = .050). The proportional hazards assumption was not met for immune-mediated ocular disease or preexisting eyelid/adnexal abnormality; the corresponding HRs represent average associations over follow-up. No multivariable model was fitted for infectious keratitis. CONCLUSIONS: Infectious keratitis and endophthalmitis remain serious complications after Boston Type I KPro. Endophthalmitis occurred most often in the first postoperative year but continued during long-term follow-up. Immune-mediated ocular disease was associated with endophthalmitis in the adjusted model, whereas prior HSV keratitis showed a borderline adjusted association. Preexisting eyelid/adnexal abnormality was associated with infectious keratitis in univariable analysis; this finding is exploratory. Long-term surveillance and careful management of the ocular surface and eyelids remain central to postoperative care.
Common Questions
What is Endophthalmitis?
Endophthalmitis is a severe inflammation of the inner tissues and fluids of the eye, most often caused by infection after eye surgery, an injection into the eye, an injury, or spread of infection through the bloodstream. Symptoms include sudden eye pain, redness and loss of vision. It is an emergency treated with antibiotic or antifungal medicine injected into the eye, and sometimes surgery to remove the vitreous gel.
How many clinical trials are available for Endophthalmitis?
RareWays currently indexes 34 clinical trials for Endophthalmitis. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Endophthalmitis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Endophthalmitis.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.